The Na þ /I À symporter (NIS) is a membrane glycoprotein that facilitates the uptake of iodine into thyroid follicular cells. Recently, we and others have demonstrated the feasibility of imaging subcutaneous xenografts expressing exogenous NIS, suggesting that NIS may serve as an imaging reporter gene to monitor vector delivery and therapeutic gene expression. In this study, we established NIS-expressing pulmonary tumors in nude mice to investigate the minimal tumor size required for in vivo detection of pulmonary tumors by single photon emission computed tomography (SPECT) with pinhole collimation. In order to define the anatomic location of NIS-expressing tumor nodules detectable by SPECT, we performed simultaneous, dual-isotope imaging. We injected 1 mCi 99m Tc-MAA via tail vein to image pulmonary perfusion and injected 1 mCi Na 125 I intraperitoneally to image NIS-expressing tumors. Fused images showed that 99m Tc-MAA perfusion defects correlated with NIS-mediated 125 I uptake. Post-mortem analysis revealed that tumors 3 mm in diameter could be detected by SPECT with pinhole collimation. These studies demonstrate the feasibility of SPECT to detect pulmonary tumors expressing exogenous NIS in mice.
T he sodium/iodide symporter (NIS) is an intrinsic membrane glycoprotein with 13 putative transmembrane domains. Electrophysiologic studies have shown that NIS functions by cotransporting one I À ion with two Na þ ions into cells. 1 In addition, other selected anions (e.g. ReO 4 and TcO 4 ) are readily transported by NIS. Consequently, NIS-expressing cells will uptake radionuclides such as 131 Re, resulting in their intracellular accumulation. In tissues where NIS protein is endogenously expressed, including the thyroid, [2] [3] [4] stomach, 5, 6 salivary gland, [7] [8] [9] and lactating breast, 10, 11 the accumulation of these radionuclides can be detected in vivo by nuclear imaging. Use of these radioisotopes has long been essential to the diagnosis and treatment of thyroid diseases, 12 and numerous studies have been conducted to investigate the use of NISmediated radionuclide accumulation in the diagnosis and treatment of nonthyroid malignancies.
Since the cloning of NIS in 1996, 3, 4 interest in the use of NIS as an imaging reporter gene has risen for several reasons. First, NIS is not a foreign gene; hence, it is nonimmunogenic. Second, the tissue expression profile of endogenous NIS protein is limited; as a result, imaging of exogenous NIS function can be performed in a wide variety of tissues due to limited background interference. Third, NIS mediates the uptake of radioisotopes and simple radiopharmaceuticals; therefore, complicated synthesis and labeling of substrate molecules is not required for imaging. Fourth, the radionuclides employed are specific to NIS-expressing cells, which reduces unwanted background signal. Fifth, both NIS-mediated radionuclide uptake and background clearing are rapid, which makes imaging feasible. In summary, NIS and its radionuclides possess qualities favorable for an imaging reporter gene toward the monitoring and optimization of gene delivery and expression.
The first imaging trial in tumors expressing exogenous NIS was performed using autoradiography of rats carrying NIS-transfected FRTL-Tc cells, a transformed rat thyroid cell line that has lost its endogenous NIS expression. 13 Subsequently, in vivo planar scintigraphy has been performed on NIS-transduced A375 human melanoma cells, 14 LNCaP human prostate carcinoma cells, 15 MH3924 hepatoma cells, 16 SiHa human cervical carcinoma cells, 17 MATLyLu (MLL) rat prostate cancer cells, 18 F98 rat glioma cells, 19 and ARH-77 multiple myeloma cells. 20 A variety of delivery methods, including adenoviral 11, 17 and retroviral 16, 18 transduction, have been used to transfer exogenous NIS to these nonthyroid cell lines, demonstrating the broad range of cell types and delivery methods that can be employed in exogenous NIS gene delivery.
Whereas the majority of these studies exploring NIS as an imaging reporter gene have used planar scintigraphy, 124 I positron emission tomography (PET) has also been used recently to detect xenografts expressing exogenous NIS in mice. 21 To date, no studies have examined the use of single photon emission computed tomography (SPECT) to image exogenous NIS expression. Unlike PET, SPECT is more readily available and does not require positron emitting radionuclides. 22 In this study, we examine the ability of SPECT to detect NIS-expressing pulmonary tumor nodules in nude mice. We demonstrate that multiple, discrete pulmonary NIS-expressing tumors can be detected in nude mice, using 99m Tc and 125 I SPECT. Post-mortem analysis combined with dualisotope SPECT showed that tumors as small as 3 mm in diameter can be detected.
Materials and methods

Cell culture and in vivo tumor formation
The anaplastic rat prostate tumor cell line MLL were grown in RPMI media supplemented with 10% FBS, 2 mM L-glutamine, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 mg/ml sodium selenite, and 10 U penicillin/ streptomycin. The generation of MLL/NIS cells has been previously described. 18 NIS expression was maintained in these cells by the presence of 400 mg/ml G-418.
Male 2-month-old BALB/c nu/nu mice (Taconic; Germantown, NY) were housed in a sterile environment with food and water ad libitum. Pulmonary tumors were generated by tail vein injection of cells in a volume of 0.25 ml PBS.
Flow cytometry analysis of NIS expression
MLL/NIS cells (1 Â 10 6 ) were incubated with VJ2 a-NIS mAb 23 diluted 1:50 in FACS buffer (3% FBS, 0.02%. NaN 3 in PBS) at room temperature for 30 minutes. The cells were then washed once with FACS buffer and incubated with FITC-conjugated a-mouse IgG (Sigma) diluted 1:100 in FACS buffer on ice for 30 minutes. The cells were washed again in FACS buffer and resuspended in fixative buffer (1% paraformaldehyde in PBS). Fluorescence was analyzed in 5,000 cells, using Cell Quest software (Becton Dickinson). Secondary antibody alone was used as a negative control. The percentage of NIS-expressing cells was determined by gating the right side of the negative control population at 0.5%.
Immunohistochemical staining of pulmonary tumors
Formalin-fixed lung tissues were dehydrated and embedded in paraffin blocks. Sections were cut at 10 mm, deparaffinized, and rehydrated. After blocking in 3% H 2 0 2 for 5 minutes, the sections were rinsed in distilled water and placed in a steamer containing citric acid buffer (pH 5.93) for 60 minutes for antigen retrieval. Sections were incubated with polyclonal a-NIS #331 7 (1:500) in TBS þ 1% BSA for 1 hour in a humidified chamber at room temperature. The sections were rinsed in TBS and incubated with HRP-conjugated a-rabbit IgG (Cell Signaling) for 1 hour in a humidified chamber at room temperature. The slides were rinsed again in TBS and incubated with chromagen substrate (Dako) for 5 minutes in a dark chamber. After rinsing with TBS, the slides were counterstained with hematoxylin.
Radioactive iodine uptake assay Tc SPECT every 3-5 days, post-tumor injection. All SPECT studies were performed using an A-SPECTt system provided by Gamma Medica, Inc. (Northridge, CA). Animals were given an intraperitoneal (i.p.) injection of 1 mCi Na 99m TcO 4 and after 20 minutes were anesthetized using isofluorane inhalation. The animals were secured in the rotating animal holder and a nose cone was used to ensure that the animal remained sedated for the duration of SPECT acquisition. SPECT acquisition was performed using a pinhole collimator with an aperture of 1.0 mm and a 2.4 cm radius of rotation. In all, 64 projections at 60 seconds/image were collected, with a duration of 60 seconds/image. The energy window for 99m Tc was set at 141 keV 710%. Postreconstruction filtering was performed using the Butterworth, band-pass method. 
Dual
Results
NIS-transduced MLL cells can uptake radioiodine in vitro
Parental MLL cells do not express the endogenous NIS gene and are unable to uptake radioiodine (data not shown). For our studies, we utilized a stable MLL cell line that had been infected with replication-defective retrovirus expressing NIS (MLL/NIS). 18 Flow cytometry analysis using nonpermeabilized MLL/NIS cells showed that surface NIS expression was detectable in 85% of cells (Fig 1, top panel) . Analysis of NIS function showed that MLL/NIS cells had a 25-fold increase in RAIU, compared to vector-only MLL cells (Fig. 1, bottom  panel) .
Injection of higher numbers of MLL/NIS cells correlated with an earlier date of tumor nodule detection using 99m Tc SPECT Immunohistochemical staining of MLL/NIS pulmonary tumors in nude mice demonstrated NIS membrane staining in tumor cells, with no staining in the pulmonary parenchema (Fig 2, lower panel) . By contrast, NIS staining was not detectable in any of the MLL/LXSN cells, which carry the retroviral vector lacking NIS (Fig 2,  upper panel) . The majority of MLL/NIS tumors were found on the surface of the lung, although occasional tumors were also seen surrounding blood vessels (data not shown). To screen for tumors by SPECT, we injected nude mice with 2 Â 10 (Table 1) , after which animals were killed. We counted the number of tumors on the pulmonary surface and measured their maximal diameters (Table 1) . Whereas the number of tumors that developed after injection with either 2 Â 10 3 or 1 Â 10 4 cells varied, the majority of tumors had a maximal tumor diameter ranging from 1 to 3 mm. In animals injected with 1 Â 10 5 MLL/NIS cells, a large number of tumors had formed and coalesced, making accurate measurement of tumor diameters impossible (Fig. 3, bottom row) .
Multiple, distinct pulmonary tumor nodules can be detected with 99m Tc SPECT
In animals not injected with tumor cells (Fig 3, top row) , 99m Tc uptake was only detectable in tissues that express endogenous NIS, such as the stomach (St), salivary gland (SG), and thyroid gland (Th). Following injection of 1 Â 10 5 MLL/NIS cells (Fig 3, bottom row) , the tumors had coalesced, and distinct lung nodules could not be identified by SPECT. In mice injected with 1 Â 10 4 MLL/ NIS cells (Fig 3, middle row) , distinct lesions were detectable by SPECT. Multiple, discrete 99m Tc-avid lesions are clearly visible in serial transverse images generated following image reconstruction (Fig 4) . Postmortem analysis of the lungs revealed the presence of 22 Tc uptake detected by SPECT (Fig. 3, middle row) . Owing to the lack of reference points defining pulmonary anatomy in SPECT, it was not possible to precisely correlate 99m Tcvid lesions with tumor location post mortem.
Anatomic location of pulmonary MLL/NIS tumors can be defined using dual-isotope SPECT
In order to define the anatomic location of NIS-mediated radionuclide uptake detectable by SPECT, we performed simultaneous, dual-isotope imaging of MLL/NIS lung tumor nodules. Mice were given an i. 
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Post-mortem analysis of the lungs revealed the presence of eight surface tumors, three of which correlated to the location of the 125 I-avid lesions detected by SPECT (Fig 5) . All three of the tumors detectable by SPECT had a maximal diameter of at least 3 mm (two were 3 mm in diameter and one was 4 mm). By contrast, the tumors not detected by SPECT had maximal diameters less than 3 mm (one was o1 mm, one was 2 mm, and the remaining three ranged between 1 and 2 mm). Thus, we concluded that a diameter of 3 mm was sufficient for tumor detection by SPECT with pinhole collimation.
Discussion
The utility of NIS to serve as an imaging reporter gene depends on several variables that have not yet been characterized. The minimum amount of NIS expression required for optimal detection in vivo and the minimal tumor size required for optimal detection must be determined and are likely interdependent. In addition, the sensitivity and quality of NIS imaging among various radionuclides and imaging modalities, such as planar scintigraphy, SPECT, and PET, should be compared.
Finally, the utility of NIS as an imaging reporter gene will depend on the signal-to-noise ratio, which will differ based upon the tissue properties in which the tumor is located.
The minimal tumor size required for detection in vivo by nuclear imaging is affected by several variables, such as the level of NIS expression and the percentage of NISexpressing cells in targeted tumors, as well as the radionuclide employed. Our studies employed a mixed population of NIS-expressing cells, which may have contributed to the inability to detect all tumor nodules visible at necropsy using SPECT. It has recently been demonstrated that NIS-negative cells grow more rapidly than NIS-positive cells in nude mice. 24 It would be of great interest to correlate the detectability of a given tumor with the percentage of NIS-expressing cells in our animal model. Further studies will be required to determine the degree to which the percentage of NISpositive cells affects the minimal detectable tumor size. In addition, level of NIS expression will also affect the ability to detect NIS-expressing tumors. Our MLL/NIS cells express a relatively high level of NIS, displaying a 25-fold increase in radioiodide uptake in vitro. The use of a tumor model with inducible NIS expression should provide answers regarding the minimal expression level of NIS I. Although our results are not directly applicable to human studies (due to the inability to use pinhole collimation for whole lung field imaging and the weak gamma emission of 125 I), the ability to detect 125 I accumulation using SPECT in small animals is noteworthy.
125 I is commonly used in ex vivo molecular biology studies to label oligonucleotides, antibodies, ligands, and pharmaceuticals. These compounds can be iodinated relatively easily, and the long half-life 125 I (60 days) makes it favorable for longitudinal studies in vivo. Thus, 125 I SPECT could be a useful technique to determine the biologic half-life and biodistribution of a variety of iodinated compounds in preclinical small animal studies.
The feasibility of NIS as an imaging reporter gene has now been demonstrated using all three nuclear medicine imaging modalities: planar scintigraphy, SPECT, and PET. It will be interesting to compare the technical limitations and image quality of these modalities in detecting NIS-mediated radionuclide accumulation. One important capability of SPECT that differentiates it from PET is dual-isotope imaging. Dual-isotope studies are a powerful tool for investigating multiple targets simultaneously using isotopes that emit photons of different energies. In contrast, PET scanners are restricted to detection of radiopharmaceuticals emitting 511 keV. 22 In our SPECT studies, we used 125 I to image MLL/NIS tumors and 99m Tc-MAA to define pulmonary anatomy, allowing us to define the anatomic location of 125 I-avid tumors. These results demonstrate the potential use of SPECT to simultaneously analyze exogenous NIS expression with other physiologic parameters.
Both PET and SPECT studies are superior to planar scintigraphy because they permit 3D image reconstruction. In contrast, planar scintigraphy results in the loss of geometry due to compression into two dimensions and loss of sensitivity due to signal per volume averaging. The advantage of PET lies in its ability to quantify a wide variety of biochemical processes with high sensitivity. 25 The usefulness of PET in preclinical, small animal studies may be restricted, however, by the requirement for a local cyclotron, and the cost and short half-lives of the radionuclides generated. The use of SPECT to detect exogenous NIS has many potential advantages over PET, including the ability to detect readily available radionuclides, such as 131 I, 123 I, 125 I, and 99m Tc. While it is not yet clear whether PET or SPECT will provide better resolution in small animal imaging, the ease of use and lower cost of SPECT make it an attractive technique for imaging NIS function.
The ability to localize NIS-mediated radionuclide uptake anatomically will be enhanced by the addition of X-ray micro computed tomography (micro-CT). 26 CT will allow coregistration of CT-SPECT images and the selection of regions of interest on the anatomic images from the CT. These regions can then be used to extract radioisotope counts from the SPECT raw data and quantitatively analyze NIS-mediated uptake. In addition, the presence of CT will allow SPECT images to be corrected for scatter and tissue attenuation following reconstruction. The ability to accurately quantify the amount of radionuclide accumulation will be essential for the use of NIS as a surrogate marker for therapeutic gene expression in preclinical animal models.
In this study, we demonstrate that multiple, discrete NIS-expressing pulmonary tumors can be detected in vivo using 99m Tc and 125 I SPECT with pinhole collimation. The finding that a higher number of injected cells correlated with an earlier date of tumor detection indicates that a minimal number of NIS-expressing cells and/or target tissue size are required for in vivo detection. Finally, the combination of dual-isotope SPECT and post-mortem analysis shows that NIS-expressing pulmonary tumors as small as 3 mm in diameter can be detected by 125 I SPECT. SPECT imaging of NIS-expressing pulmonary tumors DK Marsee et al
